Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference
- None.
- None.
The presentation will be webcast live; a link for the webcast can be found on the Edgewise 聽and will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to:聽聽or follow us on聽,听聽,听听补苍诲听.
View original content to download multimedia:
SOURCE Edgewise Therapeutics
FAQ
When is Edgewise Therapeutics (EWTX) presenting at the Goldman Sachs Healthcare Conference 2025?
How can I watch the Edgewise Therapeutics (EWTX) Goldman Sachs conference presentation?
What is Edgewise Therapeutics (EWTX) main business focus?
Where can I find the replay of EWTX's Goldman Sachs Healthcare Conference presentation?
